Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

ABSTRACT:

Context

Acetyl-l-carnitine (ALC), a mitochondrial carrier involved in lipid oxidation and glucose metabolism, decreased systolic blood pressure (SBP), and ameliorated insulin sensitivity in hypertensive nondiabetic subjects at high cardiovascular risk.

Objective

To assess the effects of ALC on SBP and glycemic and lipid control in patients with hypertension, type 2 diabetes mellitus (T2D), and dyslipidemia on background statin therapy.

Design

After 4-week run-in period and stratification according to previous statin therapy, patients were randomized to 6-month, double-blind treatment with ALC or placebo added-on simvastatin.

Setting

Five diabetology units and one clinical research center in Italy.

Patients

Two hundred twenty-nine patients with hypertensi

SUBMITTER: Parvanova A 

PROVIDER: S-EPMC5912091 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature